July 25, 2024 Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis View Article
April 18, 2024 Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis View Article
November 15, 2023 Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis View Article
June 21, 2023 Chemomab Therapeutics Reports Positive Data from Secondary Analysis of Phase 2a Liver Fibrosis Trial in NASH Patients at EASL 2023 View Article
June 5, 2023 Chemomab Therapeutics Announces Executive Leadership Changes and Provides a Corporate Update View Article
January 3, 2023 Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver Fibrosis Biomarker Trial in NASH Patients View Article
December 21, 2022 Chemomab Reports Independent Drug Monitoring Committee Safety Review of CM-101 Phase 2 Trial in Primary Sclerosing Cholangitis View Article
June 27, 2022 Chemomab Presents Data Further Supporting the Mechanism of Action and Potential Efficacy of CM-101 in Primary Sclerosing Cholangitis View Article
